Company name
Humion AG
Company profile
Humion is a Swiss biotech startup developing next-generation TCR-based T-cell therapies for solid tumors. We decode the immune responses of cancer super responders - patients with exceptional, durable tumor control. This allows us to identify validated, tumor-reactive TCRs and translate them into precise, patient-derived therapeutics. Our lead program, Humion-1, targets NSCLC. The platform expands across solid tumors, addressing major unmet needs in oncology.
Date, time and room information
Monday, May 4, 15:45 - 16:00, room Singapore
Category
Emerging biotech company
Title of the presentation
From Super Responders to Cancer Therapies
Speaker information
| Name | Position | Institution |
|---|---|---|
| Omar Hasan Ali | Co-Founder | Humion AG |
Further information for the sponsor website
